The partnership with Neomorph positions Biogen to advance in the field of molecular glue degraders, potentially leading to significant advancements in treatment for Alzheimer's and other diseases. The financial commitment of up to $1.45 billion indicates a strong investment in future growth and innovation, which is likely to positively impact Biogen's stock in the short term.